Please assess the completion status of the following clinical trial:

Trial Title: Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of one of the following:~  * Chronic myelogenous leukemia~    * Philadelphia chromosome-positive OR~   * Molecular evidence of bcr/abl gene rearrangement~ * Acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, histiocytoses, myelodysplasia, juvenile chronic myelomonocytic leukemia, aplastic anemia, paroxysmal nocturnal hemoglobinuria, or Fanconi's anemia~    * Confirmed by cytochemistry, immunophenotyping, and/or chromosomal abnormalities~ * Multiple myeloma~ * Hereditary immunodeficiency disorders~    * Confirmed by immunologic determination~ * Sickle cell anemia or beta-thalassemia~    * Confirmed by hemoglobin electrophoresis~ * Storage disorders (e.g., Gaucher's disease, Hurler's disease, or metachromatic leukodystrophy)~    * Confirmed by metabolic testing~ * Other non-malignant conditions~* Eligible for allogeneic peripheral blood stem cell or bone marrow transplantation~PATIENT CHARACTERISTICS:~Age:~* 65 and under~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- alloSCT group (Type: None): Patients undergoing allogeneic blood or marrow stem cell transplantation (alloSCT).

Based on this trial design, predict the completion outcome and termination type (if applicable).